Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis

The Alendronate Once-Weekly Study Group, Rizzoli, R · 2002 · Journal of Bone and Mineral Research

Abstract

The aim of this study was to provide confirmation that once-weekly dosing with 70 mg of alendronate (seven times the daily oral dose) and twice-weekly dosing with 35 mg is equivalent to the 10-mg once-daily regimen and to gain more extensive safety experience with this new dosing regimen. Twelve hundred fifty-eight postmenopausal women (aged 42–95 years) with osteoporosis (bone mineral density [BMD] of either lumbar spine or femoral neck at least 2.5 SDs below peak young adult mean or prior vertebral or hip fracture) were assigned to receive oral once-weekly alendronate, 70 mg (n = 519); twice-weekly alendronate, 35 mg (n = 369); or daily alendronate 10 mg (n = 370) for a total of 2 years of double-blind experience. Mean BMD increases from baseline (95% CI) at 24 months in the once-weekly, twice-weekly, and daily treatment groups, respectively, were 6.8% (6.4, 7.3), 7.0% (6.6, 7.5), and 7.4% (6.9, 7.8) at the lumbar spine and 4.1% (3.8, 4.5), 4.3% (3.9, 4.7), and 4.3% (3.9, 4.7) at the total hip. These increases in BMD as well as the BMD increases at the femoral neck, trochanter, and total body and the reductions of biochemical markers of bone resorption (urinary cross-linked N-telopeptides of type I collagen [NTx]) and bone formation (serum bone-specific alkaline phosphatase [BSAP]) were similar for the three dosing regimens. All treatment regimens were well tolerated with a similar incidence of upper gastrointestinal (GI) adverse experiences. The incidence rates of clinical fractures, captured as adverse experiences, were similar among the groups. The 2-year results confirm the conclusion reached after 1 year that once-weekly alendronate is therapeutically equivalent to daily dosing, providing patients with a more convenient dosing option that may potentially enhance adherence to therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1359/jbmr.2002.17.11.1988

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 31

  1. Greenberg, 1984, Overview of patient compliance with medication dosing: A literature review, Clin Ther, 6, 592
  2. Lau, 1996, Non-compliance in elderly people: Evaluation of risk factors by longitudinal data analysis, Pharm World Sci, 18, 63, 10.1007/BF00579707 · DOI
  3. Venturini, 1999, Compliance with sulfonylureas in a health maintenance organization: A pharmacy record-based study, Ann Pharmacother, 33, 281, 10.1345/aph.18198 · DOI
  4. Liberman, 1995, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis, N Engl J Med, 333, 1437, 10.1056/NEJM199511303332201 · DOI · Paper page
  5. Black, 1996, Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2 · DOI · Paper page
  6. Pols, 1999, Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study, Osteoporos Int, 9, 461, 10.1007/PL00004171 · DOI · Paper page
  7. Hochberg, 1999, Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis, Arthritis Rheum, 42, 1246, 10.1002/1529-0131(199906)42:6<1246::AID-ANR22>3.0.CO;2-U · DOI · Paper page
  8. Bauer, 2000, Upper gastrointestinal tract safety profile of alendronate: The Fracture Intervention Trial, Arch Intern Med, 160, 517, 10.1001/archinte.160.4.517 · DOI · Paper page
  9. Bone, 2000, Weekly administration of alendronate: Rationale and plan for clinical assessment, Clin Ther, 22, 15, 10.1016/S0149-2918(00)87974-6 · DOI
  10. Schnitzer, 2000, Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis, Aging Clin Exp Res, 12, 1, 10.1007/BF03339822 · DOI · Paper page
  11. Black, 1995, Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fractures, J Bone Miner Res, 10, 890, 10.1002/jbmr.5650100610 · DOI · Paper page
  12. Faulkner, 1995, Quality control of DXA instruments in multicenter trials, Osteoporos Int, 5, 218, 10.1007/BF01774010 · DOI
  13. ICH Harmonised Tripartite Guideline, 1999, Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group, Stat Med, 18, 1905
  14. Genant, 1993, Vertebral fracture assessment using a semiquantitative technique, J Bone Miner Res, 8, 1137, 10.1002/jbmr.5650080915 · DOI · Paper page
  15. Black, 2000, Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial, J Clin Endocrinol Metab, 85, 4118, 10.1210/jcem.85.11.6953 · DOI · Paper page
  16. Thompson, 2000, Consistency of effect of alendronate on reduction in risk of hip fractures, J Am Geriatr Soc, 48, S56
  17. Faulkner, 2000, Bone matters: Are density increases necessary to reduce fracture risk?, J Bone Miner Res, 15, 183, 10.1359/jbmr.2000.15.2.183 · DOI · Paper page
  18. Garnero, 1996, Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study, J Bone Miner Res, 11, 1531, 10.1002/jbmr.5650111021 · DOI · Paper page
  19. Riis, 1996, Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture: A 15-year follow-up study, Bone, 19, 9, 10.1016/8756-3282(96)00102-0 · DOI · Paper page
  20. Harris, 1993, Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy, Am J Med, 95, 557, 10.1016/0002-9343(93)90350-X · DOI · Paper page
  21. Recker, 2000, A new treatment paradigm: Quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): Results of a 3-year trial, Osteoporos Int, 11, S209
  22. Chesnut, 1995, Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling, Am J Med, 99, 144, 10.1016/S0002-9343(99)80134-X · DOI · Paper page
  23. Devogelaer, 1996, Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis, Bone, 18, 141, 10.1016/8756-3282(95)00436-X · DOI · Paper page
  24. Adami, 1995, Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis, Bone, 17, 383, 10.1016/S8756-3282(95)00262-6 · DOI
  25. Garnero, 1994, Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment, J Clin Endocrinol Metab, 79, 1693
  26. Bone, 2002, Once-weekly alendronate 70 mg: Sustained suppression of bone resorption, Osteoporos Int, 13, S29
  27. Chavassieux, 1997, Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis, J Clin Invest, 100, 1475, 10.1172/JCI119668 · DOI · Paper page
  28. Seedor, 1991, The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats, J Bone Miner Res, 6, 339, 10.1002/jbmr.5650060405 · DOI · Paper page
  29. DeGroen, 1996, Esophagitis associated with the use of alendronate, N Engl J Med, 335, 1016, 10.1056/NEJM199610033351403 · DOI · Paper page
  30. Reginster, 2000, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis, Osteoporos Int, 11, 83, 10.1007/s001980050010 · DOI · Paper page
  31. Peter, 1998, Esophageal irritation due to alendronate sodium tablets: Possible mechanisms, Dig Dis Sci, 43, 1998, 10.1023/A:1018894827961 · DOI

Cited by

See all 221

Metadata

Authors
The Alendronate Once-Weekly Study Group, & Rizzoli, R.
Venue
Journal of Bone and Mineral Research
Published
2002-11-01
Volume
17
Issue
11
Pages
1988-1996
ISSN
  • 0884-0431 (ISSN-L)
  • 1523-4681
OpenAlex
W2126162095
Cited by
221
References
2
FWCI
19.56
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis. https://app.cochat.ai/papers/10.1359/jbmr.2002.17.11.1988
The paper
The Alendronate Once-Weekly Study Group, & Rizzoli, R. (2002). Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.2002.17.11.1988

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.